{"id":"perfusion-of-treatment-rituximab","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"20-40","effect":"Infections (including serious infections)"},{"rate":"5-15","effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. By binding to CD20, it triggers immune-mediated destruction of B cells through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This B cell depletion reduces autoimmune and inflammatory responses in conditions driven by pathogenic B cells.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:25.996Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (moderate to severe)"},{"name":"Granulomatosis with polyangiitis (GPA)"},{"name":"Microscopic polyangiitis (MPA)"},{"name":"B-cell non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT05758831","phase":"PHASE3","title":"RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.","status":"RECRUITING","sponsor":"Rennes University Hospital","startDate":"2023-06-01","conditions":"Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis","enrollment":386},{"nctId":"NCT06906549","phase":"PHASE4","title":"Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-07-11","conditions":"Rheumatoid Arthritis (RA), Rituximab (RTx)","enrollment":260},{"nctId":"NCT05682196","phase":"PHASE2","title":"Rituximab in Patients With Acute Rheumatic Fever","status":"SUSPENDED","sponsor":"African Academy of Methodology and Statistics","startDate":"2023-01-05","conditions":"Rheumatic Heart Disease in Children","enrollment":234},{"nctId":"NCT03154385","phase":"NA","title":"Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-03-13","conditions":"Immune Thrombocytopenia","enrollment":15},{"nctId":"NCT02867553","phase":"PHASE3","title":"Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions","status":"UNKNOWN","sponsor":"CHU de Reims","startDate":"2011-10","conditions":"Indolent Cutaneous B Cell Lymphomas","enrollment":36},{"nctId":"NCT00525616","phase":"PHASE3","title":"Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2008-12","conditions":"Bullous Pemphigoid","enrollment":18},{"nctId":"NCT01361191","phase":"PHASE2","title":"Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2007-06","conditions":"Diffuse Large B-cell Lymphoma, Follicular Grade 3B Lymphoma","enrollment":71},{"nctId":"NCT00664599","phase":"PHASE2","title":"Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2006-04","conditions":"Behcet's Syndrome","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Perfusion of treatment Rituximab","genericName":"Perfusion of treatment Rituximab","companyName":"Rennes University Hospital","companyId":"rennes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Rheumatoid arthritis (moderate to severe), Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}